1. Home
  2. EUDA vs SGMT Comparison

EUDA vs SGMT Comparison

Compare EUDA & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EUDA
  • SGMT
  • Stock Information
  • Founded
  • EUDA 2021
  • SGMT 2006
  • Country
  • EUDA Singapore
  • SGMT United States
  • Employees
  • EUDA N/A
  • SGMT N/A
  • Industry
  • EUDA Blank Checks
  • SGMT
  • Sector
  • EUDA Finance
  • SGMT
  • Exchange
  • EUDA Nasdaq
  • SGMT Nasdaq
  • Market Cap
  • EUDA 139.3M
  • SGMT 128.5M
  • IPO Year
  • EUDA N/A
  • SGMT 2023
  • Fundamental
  • Price
  • EUDA $3.71
  • SGMT $2.52
  • Analyst Decision
  • EUDA
  • SGMT Strong Buy
  • Analyst Count
  • EUDA 0
  • SGMT 6
  • Target Price
  • EUDA N/A
  • SGMT $25.67
  • AVG Volume (30 Days)
  • EUDA 105.8K
  • SGMT 372.8K
  • Earning Date
  • EUDA 01-01-0001
  • SGMT 03-12-2025
  • Dividend Yield
  • EUDA N/A
  • SGMT N/A
  • EPS Growth
  • EUDA N/A
  • SGMT N/A
  • EPS
  • EUDA N/A
  • SGMT N/A
  • Revenue
  • EUDA $3,811,496.00
  • SGMT N/A
  • Revenue This Year
  • EUDA $66.63
  • SGMT N/A
  • Revenue Next Year
  • EUDA $119.95
  • SGMT N/A
  • P/E Ratio
  • EUDA N/A
  • SGMT N/A
  • Revenue Growth
  • EUDA N/A
  • SGMT N/A
  • 52 Week Low
  • EUDA $1.64
  • SGMT $2.39
  • 52 Week High
  • EUDA $6.30
  • SGMT $7.38
  • Technical
  • Relative Strength Index (RSI)
  • EUDA 44.94
  • SGMT 24.66
  • Support Level
  • EUDA $3.59
  • SGMT $3.89
  • Resistance Level
  • EUDA $4.04
  • SGMT $4.24
  • Average True Range (ATR)
  • EUDA 0.21
  • SGMT 0.30
  • MACD
  • EUDA -0.02
  • SGMT -0.12
  • Stochastic Oscillator
  • EUDA 18.75
  • SGMT 0.00

About EUDA EUDA Health Holdings Limited

EUDA Health Holdings Ltd is a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem aimed at making healthcare affordable and accessible, The company's proprietary unified AI platform quickly assesses a patient's medical history, triages a condition, digitally connects patients with clinicians, and predicts optimal treatment outcomes. The company caters to all stages of care, including wellness and prevention, urgent care and emergencies, pre-existing conditions, and aftercare services. The company operates in two segments namely Medical services and property management services, out of which the company derives its maximum revenue from Medical services.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: